🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In our 8th in-person consortium meeting, medical and technical partners got to collaborate closely on testing hypotheses and developing workflows on the platform through a series of workshops, enabling real-time troubleshooting. Read more: mes-cobrad.eu/8th-project-me… #neurology #IT

Our Pilots page has been updated! Learn more about the #mescobrad algorithms and protocols here: mes-cobrad.eu/pilots #medicine #neurology #IT #CoBraD #Horizon2021

Patient with recurrent seizures Diagnosis?

Consider anti-CD20 disease-modifying therapies as high-efficacy options in patients with MS who survive progressive multifocal leukoencephalopathy. Learn more in this Clinical/Scientific Note: bit.ly/3XmeIWg #Neurology #NeuroTwitter

This narrative review summarizes the current understanding of poststroke epileptogenesis, risks, prognostic models, primary and secondary prophylaxis, and proposes strategies to advance the research, particularly aimed at preventing poststroke #epilepsy: bit.ly/4ci2S3W

A study published in iScience journal suggests that #psilocybin does not impair learning & may enhance exploratory behavior. The study marks the first investigation into how psilocybin influences reinforcement learning. psypost.org/psilocybin-enh…

The influence of #psilocybin on subconscious and conscious emotional learning cell.com/iscience/fullt… #OpenAccess iScience journal

This study provides Class III evidence that terazosin, doxazosin, and alfuzosin use reduces the rate of developing dementia with Lewy bodies in adult men: bit.ly/4brnqpz

It might be possible to treat range of neurodegenerative conditions, such as #Alzheimers, with #genetherapy that makes brain cells produce antibodies. Tests on human mini-brains show that the antibodies can reduce levels inside brain cells of tau protein newscientist.com/article/243866…

Join us! "Transforming Brain Disorder Care with Real-World Data: Key Insights from the MES-CoBraD Project." Don’t miss the chance to explore the future of brain disorder research with top experts! #MESCoBraD #BrainHealth 🗓️ 06/12/2024 🕒 11:00 CET 🔗 mes-cobrad.eu/Key-Insights-f…

How can real-world data & AI transform brain disorder diagnosis? Our final #MESCoBraD webinar shares 3 years of groundbreaking research in advancing patient care. Don’t miss it! 🗓️ 06/12/2024 📷 11:00 CET 🔗mes-cobrad.eu/Key-Insights-f… #BrainHealth #DigitalHealth

🚨Attention #RDM, #AI, & #DataScience enthusiasts! For the last 3,5 years, LIBER has participated in H2020MESCoBraD. As this innovative project comes to a close, join us for the final webinar & learn about future of brain disorder research. Don't miss out!👉ow.ly/FOBe50U6TXp

The MES-CoBraD project is reshaping brain disorder care with real-world data! In our last event, we’ll share insights, innovations, and lessons learned. Register now! #MESCoBraD #BrainHealth 🗓️ 06/12/2024 🕒 11:00 CET 🔗 mes-cobrad.eu/Key-Insights-f…

Want to know how #MESCoBraD is advancing diagnosis & treatment of brain disorders? Join our experts as they share the latest findings from this Horizon Europe project. Secure your spot today! #HealthcareInnovation #BrainDisorders

The #MESCoBraD project’s final webinar is almost here! Discover key takeaways & insights from top experts after 3 years of research insights and advancements. Click on the link below to register! #MESCoBraD #BrainHealth 🗓️ 06/12/2024 🕒 11:00 CET 🔗 mes-cobrad.eu/Key-Insights-f…

👏#Athens becomes the first city in Europe to eliminate municipal fees for energy-poor households! Introduced by Mayor Haris Doukas, this groundbreaking initiative directly alleviates financial burdens on those affected by energy poverty. Read⬇️netzerocities.eu/2024/12/16/a-b… #MissionCities

This year's World Brain Day is the first one after the completion of the MES-CoBraD project! Our work and accomplishments were outlined in a new article posted by HaDEA. Read more here: mes-cobrad.eu/node/105 #H2020 #HorizonEU #MESCoBraD #HealthcareInnovation #BrainDisorders